TRANSFORMING LIVES FOREPIDERMOLYSIS BULLOSA

Targeting dysfunctional healing with immune-modulating peptides

Xinnate is developing TCP-25 for novel pharmaceutical therapies that restores and accelerates healing by targeting both inflammation and infection.

Inspired by the body’s own defense mechanisms, TCP-25 was developed from thrombin-derived peptides discovered by Professor Arthur Schmidtchen, MD, and team at Lund University. By rebalancing the immune response, TCP-25 offers a powerful therapeutic approach for complex skin disorders.

Our vision:
We transform lives for patients facing complex skin diseases by integrating groundbreaking scientific insights into everyday clinical practice.